Jm. Abrahams et al., Risk factors affecting survival after brain metastases from non-small celllung carcinoma: a follow-up study of 70 patients, J NEUROSURG, 95(4), 2001, pp. 595-600
Object. The authors present their experience with the treatment of brain me
tastases from non-small cell lung carcinoma (NSCLC).
Methods. A retrospective review was conducted in which records from 74 pati
ents treated at the authors' institution between 1994 and 1999 were assesse
d. Survival and functional outcome were reviewed relative to individual pat
ient variables. The median survival time was 12.9 months, with 1-, 2-, and
5-year survival milestones reached by 52.2%, 30.7%, and 18.1% of patients,
respectively. Patients were stratified into groups composed of those with s
ynchronous brain metastases (tumors diagnosed within 3 months of NSCLC) and
metachronous brain metastases (tumors diagnosed 3 months after NSCLC). The
median survival time and 5-year survival rate were 18 months and 28.9% for
metachronous, compared with 9.9 months and 0% for synchronous brain metast
ases. In univariate analyses, the stage of brain metastases, an initial Kar
nofsky Performance Scale (KPS) score of 90 or less, and conservative therap
y for NSCLC were associated with worse outcomes (p < 0.05). In analyses in
which tumors were stratified by synchronous compared with metachronous brai
n metastases, a preoperative KPS score of 90 or less and radiation therapy
(RT) alone for brain metastases were associated with worse outcomes in pati
ents with metachronous brain metastases but not with synchronous tumors (p
< 0.05). When stratified by preoperative KPS score, the synchronous brain m
etastases stage or treatment of brain metastases with RT alone were associa
ted with worse outcome in patients with KPS scores of 100, but had no disce
rnible effect on patients with KPS scores of 90 or less (p < 0.05).
Conclusions. The tumor stage and preoperative KPS score were significantly
associated with survival. Craniotomy plus RT significantly improved the pro
gnosis in patients with metachronous brain metastases or those with a preop
erative KPS score of 100.